Key stats
About Virtus LifeSci Biotech Clinical Trials ETF
Home page
Inception date
Dec 16, 2014
Structure
Open-Ended Fund
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Virtus Advisers LLC
Distributor
VP Distributors LLC
BBC focuses on biotech companies with lead drugs that are still in various phases of clinical trials and not yet approved marketing. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. It excludes companies with a lead drug candidate that’s still in preclinical testing or research stage, prior to entering into human clinical trials. Also excluded are the following 12 distinct sub-industries: Animal Health, Diversified Healthcare, Investment Management, Healthcare Services, Non-Healthcare, Large Pharmaceuticals, Specialty Pharmaceuticals, Medical Devices, Vaccines, Nutraceuticals, OTC Healthcare, or Tools. As such, investors looking for broad biotech exposure, won't find it in BBC. The Index Committee utilizes various public data sources to select portfolio holdings, including, SEC filings, public documents from the U.S. FDA, company press releases and official corporate websites.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.93%
Health Technology97.39%
Commercial Services1.53%
Bonds, Cash & Other1.07%
Cash1.07%
Stock breakdown by region
North America86.67%
Europe12.83%
Asia0.51%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BBC invests in stocks. The fund's major sectors are Health Technology, with 97.39% stocks, and Commercial Services, with 1.53% of the basket. The assets are mostly located in the North America region.
BBC top holdings are Akero Therapeutics, Inc. and Soleno Therapeutics Inc, occupying 1.84% and 1.81% of the portfolio correspondingly.
BBC last dividends amounted to 0.24 USD. The year before, the issuer paid 0.08 USD in dividends, which shows a 65.63% increase.
BBC assets under management is 9.82 M USD. It's fallen 33.37% over the last month.
BBC fund flows account for 2.95 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, BBC pays dividends to its holders with the dividend yield of 1.29%. The last dividend (Dec 27, 2024) amounted to 0.24 USD. The dividends are paid annually.
BBC shares are issued by Virtus Investment Partners, Inc. under the brand Virtus. The ETF was launched on Dec 16, 2014, and its management style is Passive.
BBC expense ratio is 0.79% meaning you'd have to pay 0.79% of your investment to help manage the fund.
BBC follows the LifeSci Biotechnology Clinical Trials Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BBC invests in stocks.
BBC price has fallen by −0.49% over the last month, and its yearly performance shows a −29.39% decrease. See more dynamics on BBC price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −5.13% over the last month, showed a −10.66% decrease in three-month performance and has decreased by −28.83% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −5.13% over the last month, showed a −10.66% decrease in three-month performance and has decreased by −28.83% in a year.
BBC trades at a premium (0.01%) meaning the ETF is trading at a higher price than the calculated NAV.